Q-omics provides the consensus-scored FAM71A profile across patient tissues and cancer cell-line models. FAM71A expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, FAM71A is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, FAM71A RNA expression shows 5,973 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, HNSC, and STAD as cancer lineages where FAM71A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM71A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM71A survival associations across molecular data types. FAM71A RNA expression shows survival associations in the most cancer types (11), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM71A RNA expression–survival associations across cancer types. High FAM71A expression shows unfavorable associations in THYM, COAD, ESCA, LGG, KIRC and LUSC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for FAM71A RNA expression.
This table summarizes FAM71A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM71A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM71A shows lower tumor expression in HNSC, LUAD, BRCA, LUSC, THCA and BLCA. The HNSC box plot shows higher FAM71A RNA expression in normal versus tumor tissue (log2 FC = −0.045, t-test p < 0.001).
This table shows molecular features associated with FAM71A in patient tissues and cancer cell lines. In patient samples, FAM71A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM71A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
